TGFBI and nasopharyngeal carcinoma: This observation was further confirmed using immunohistochemistry (IHC; n = 30), wherein patients with greater than median TGFBI immunostaining (cytoplasmic or membrane) had a higher 5-year OS of 80 vs. 60% for patients with low TGFBI immunoexpression (p = 0.024; Fig. 3g, Supplementary Figure S3c), corroborating the clinical significance of TGFBI in mediating NPC survival.